Radiance Research AcademyInternational Journal of Current Research and Review2231-21960975-5241182EnglishN2026January30Healthcare Evaluation of Treatment Outcomes and Safety of Erythrocytapheresis versus Phlebotomy in Adults with Hereditary Hemochromatosis   Patrycja Machno, Aleksandra Salagierska, Zofia Gniadek, Wiktoria Jurczyk-Florkiewicz, Agata Pszczolka, Gabriela Bajor, Kacper Melka, Mikolaj Szulewski, Patryk Matuszczak, Joanna Kozak       English0106Patrycja MachnoEnglish Aleksandra SalagierskaEnglish Zofia GniadekEnglish Wiktoria Jurczyk-FlorkiewiczEnglish Agata PszczolkaEnglish Gabriela BajorEnglish Kacper MelkaEnglish Mikolaj SzulewskiEnglish Patryk MatuszczakEnglish Joanna KozakEnglish Hereditary hemochromatosis is a common genetic disorder characterized by progressive iron overload that may lead to multi organ damage if untreated. The aim of this review was to compare the efficacy, safety, and treatment characteristics of erythro cytapheresis and phlebotomy in adults with HFE-related hereditary hemochromatosis. A literature search was conducted using PubMed and Google Scholar to identify studies published after 2012 that directly compared both treatment modalities in adult patients. Available evidence indicated that both phlebotomy and erythrocytapheresis were effective in reducing iron overload and achieved comparable long-term control of serum ferritin and transferrin saturation. Erythrocytapheresis allowed removal of a greater amount of iron per procedure and was associated with fewer treatment sessions and a shorter induction phase. Adverse events were predominantly mild and transient. Although the cost per procedure was higher for erythrocytapheresis, overall treat ment costs appeared comparable when reduced procedure frequency and indirect costs were considered. Phlebotomy remains the first-line therapy for most patients; however, erythrocytapheresis represented a safe and effective alternative in selected individuals, particularly when rapid iron depletion or improved treatment tolerability was required. EnglishErythrocytapheresis; Hereditary hemochromatosis; Iron overload; Phlebotomy; Safety; Treatment outcomeshttp://ijcrr.com/abstract.php?article_id=4889http://ijcrr.com/article_html.php?did=4889 1. Adams PC, Ryan JD. Diagnosis and treatment of hemochro matosis. Clin Gastroenterol Hepatol. 2025;23(9):1477–1485. https://doi.org/10.1016/j.cgh.2024.10.041 2. Pauwels NS, De Buck E, Compernolle V, Vandekerckhove P. Worldwide policies on haemochromatosis and blood donation: a survey among blood services. Vox Sang. 2013;105(2):121–128. https://doi.org/10.1111/vox.12038 3. Ong SY, Gurrin LC, Dolling L, Dixon J, Nicoll AJ, Wolthuizen M, et al. Reduction of body iron in HFE-related haemochroma tosis and moderate iron overload: the Mi-Iron trial. Lancet Hae matol. 2017;4(12):e607–e614. https://doi.org/10.1016/s2352 3026(17)30214-4 4. Powell LW, Seckington RC, Deugnier Y. Haemochromatosis. Lancet. 2016;388(10045):706–716. https://doi.org/10.1016/ s0140-6736(15)01315-x 5. Sohal A, Kowdley KV. A review of new concepts in iron over load. Gastroenterol Hepatol (N Y). 2024;20(2):98–107. https:// pubmed.ncbi.nlm.nih.gov/38414914/ 6. Asimakopoulou A, Weiskirchen S, Weiskirchen R. Pathogene sis, diagnostics, and treatment of hereditary haemochromatosis: a 150-year understanding of an iron overload disorder. Eur Med J. 2017;2(4):122–133. https://doi.org/10.33590/emj/10310080 7. Spodymek A, Lachowicz J, Szymczyk-Nu?ka M. Hemochro matosis—an insidious genetic disease. J Transfus Med Hemost. 2025;18:93–102. https://doi.org/10.5603/jtmh.108276 8. Ferrari B, Peyvandi F. Hemochromatosis classification: update and recommendations by the BIOIRON Society. Blood. Machno et al.: Evaluation of treatment outcomes and safety of erythrocytapheresis versus phlebotomy 2020;136(19):2125–2132. https://doi.org/10.1182/ blood.2021011338 9. Alvarenga AM, Brissot P, Santos PCJL. Haemochromatosis re visited. World J Hepatol. 2022;14(11):1931–1939. https://doi. org/10.4254/wjh.v14.i11.1931 10. Girelli D, Marchi G, Busti F. Diagnosis and management of hereditary hemochromatosis: lifestyle modification, phle botomy, and blood donation. Hematol Am Soc Hematol Educ Program. 2024;2024:434–440. https://doi.org/10.1182/hematol ogy.2024000568 11. Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diag nosis, and treatment. Gastroenterology. 2010;139(2):393–408. https://doi.org/10.1053/j.gastro.2010.06.013 12. Porto G, Brissot P, Swinkels DW, Zoller H, Kamarainen O, Pat ton S, et al. EMQN best practice guidelines for the molecular ge netic diagnosis of hereditary hemochromatosis. Eur J Hum Gen et. 2016;24(4):479–495. https://doi.org/10.1038/ejhg.2015.128 13. De Graaff B, Neil A, Sanderson K, Yee KC, Palmer AJ. Costs as sociated with hereditary haemochromatosis in Australia: a cost of-illness study. Aust Health Rev. 2017;41(3):254–267. https:// doi.org/10.1071/AH15188 14. Brissot P, Cavey T, Ropert M, Guggenbuhl P, Loréal O. Genetic hemochromatosis: pathophysiology, diagnostic and therapeutic management. Presse Med. 2017;46(12 Pt 2):e288–e295. https:// doi.org/10.1016/j.lpm.2017.05.037 15. Panch SR, Yau YY, West K, Diggs K, Sweigart T, Leitman SF. Initial serum ferritin predicts number of therapeutic phleboto mies to iron depletion in secondary iron overload. Transfusion. 2015;55(3):611–622. https://doi.org/10.1111/trf.12854 16. Rombout-Sestrienkova E, Nieman FHM, Essers BAB, Van Noord PAH, Janssen MCH, Van Deursen CTBM, et al. Eryth rocytapheresis versus phlebotomy in the initial treatment of HFE hemochromatosis patients: results from a randomized trial. Transfusion. 2012;52(3):470–477. https://doi.org/10.1111/ j.1537-2995.2011.03292.x 17. Sundic T, Hervig T, Hannisdal S, Assmus J, Ulvik RJ, Olaus sen RW, et al. Erythrocytapheresis compared with whole blood phlebotomy for the treatment of hereditary haemochromato sis. Blood Transfus. 2014;12(Suppl 1):S84–S89. https://doi. org/10.2450/2013.0128-13 18. Murphree CR, Nguyen NN, Raghunathan V, Olson SR, De Loughery T, Shatzel JJ. Diagnosis and management of heredi tary haemochromatosis. Vox Sang. 2020;115(4):255–262. htt ps://doi.org/10.1111/vox.12896 19. Rombout-Sestrienkova E, Winkens B, Essers BAB, Nieman FHM, Noord PAH, Janssen MCH, et al. Erythrocytapher esis versus phlebotomy in the maintenance treatment of HFE hemochromatosis patients: results from a randomized crossover trial. Transfusion. 2016;56(1):261–270. https://doi.org/10.1111/ trf.13328 20. Rombout-Sestrienkova E, Winkens B, van Kraaij M, van Deursen CTBM, Janssen MCH, Rennings AMJ, et al. A predic tive model for estimating the number of erythrocytapheresis or phlebotomy treatments for patients with naïve hereditary hemo chromatosis. J Clin Apher. 2021;36(3):340–347. https://doi. org/10.1002/jca.21867 21. Rombout-Sestrienkova E, van Kraaij MGJ, Koek GH. How we manage patients with hereditary haemochromatosis. Br J Hae matol. 2016;175(5):759–770. https://doi.org/10.1111/bjh.14376 22. Evers D, Kerkhoffs JL, Van Egmond L, Schipperus MR, Wijermans PW. The efficiency of therapeutic erythrocytapher esis compared to phlebotomy: a mathematical tool for predict ing response. J Clin Apher. 2014;29(3):133–138. https://doi. org/10.1002/jca.21303 23. ?ehá?ek V, Bláha M, Jiroušová H, ?ernohorská J, Papoušek P. Therapeutic erythrocytapheresis in the ini tial treatment of hereditary hemochromatosis. Acta Med (Hradec Kralove). 2012;55(4):180–185. https://doi. org/10.14712/18059694.2015.43 24. Burna? IL, Bojani? I, Mazi? S, Luki? M, ?epuli? BG. Perfor mance and safety of therapeutic erythrocytapheresis in poly cythemia and hemochromatosis treatment: single centre experi ence. Hematol Transfus Cell Ther. 2024;46:S103–S108. https:// doi.org/10.1016/j.htct.2024.05.011 25. Grabmer C, Schmid D, Mayer G, Aigner E, Wagner A, Streif D, et al. Iron depletion with a novel apheresis system in patients with hemochromatosis. Transfusion. 2015;55(5):996–1000. htt ps://doi.org/10.1111/trf.12949

Radiance Research AcademyInternational Journal of Current Research and Review2231-21960975-5241182EnglishN2026January30Healthcare Efficacy of Unani Formulations in the Management of Haemorrhagic Ovarian Cyst: A Case Report     English0711Samira Khatoon ChoudharyEnglish Shavana FathimaEnglish Wajeeha BeguEnglish Introduction: Haemorrhagic ovarian cysts (HOCs) are functional cysts that develop due to bleeding into follicular or corpus luteum cysts. They may present with abdominal pain, menstrual irregularities, or remain asymptomatic. Conventional manage ment often involves observation or surgery, but surgical intervention carries risks of ovarian damage and recurrence. In Unani, a haemorrhagic ovarian cyst is regarded as a condition resulting from Fasade Dam and the dominance of Balgham. It can be managed with Unani formulations that exhibit Mohallil-e-Awram, Moaddil-e-Dam, and Nafae Sudda-e-Har properties. Unani literature highlights several single and compound drugs that are believed to effectively dissolve the cyst and reduce the need for surgical intervention. Case Report: A 32-year-old married, primary infertile woman presented with painful scanty menses, lower abdominal heavi ness, backache, and urinary discomfort. Ultrasonography revealed a right ovarian haemorrhagic cyst measuring 4.0 × 3.7 cm. She was treated with a combination of Unani medicines—Majoon Dabidul Ward, Itrifal Ghudadi, Majoon Mocharas, and Sharbat Zanjabeel—administered orally for a period of three months. Results: The patient showed marked improvement in dysmenorrhea and abdominal symptoms by the third follow-up. A repeat ultrasound performed three months later confirmed the complete resolution of the ovarian cyst. Conclusion: Unani formulations demonstrated significant efficacy in resolving HOC without surgical intervention, suggesting their potential as safe and holistic alternatives in gynaecological practice. Further clinical studies are recommended to validate these findings. EnglishHaemorrhagic ovarian cyst, unani medicines, functional cyst, majoon Dabidul ward, Itrifal Ghudadi, non-surgical management.http://ijcrr.com/abstract.php?article_id=4890http://ijcrr.com/article_html.php?did=4890 1. Shamshad N, Ahmad S. Efficacy of Unani medicine in haemor rhagic ovarian cyst. International Journal of Unani and Integra tive Medicine. 2024;8(3):39-42. doi:10.33545/2616454X.2024. v8.i3a.296. 2. Abbas AM, Amin MT, Tolba SM, Ali MK. Haemorrhagic ovar ian cysts: Clinical and sonographic correlation with the manage ment options. Middle East Fertility Society Journal. 2016 Mar 1;21(1):41-5. doi: 10.1016/j.mefs.2015.08.001 3. Ding Z, Zhang D, Ying W, Wang J. Sonographic value in diag nosis of haemorrhagic ovarian cysts. European Journal of Gy naecological Oncology. 2010 Jan 1;31(1):87-9. doi:10.12892/ ejgo20100187. 4. Jain KA. Sonographic spectrum of haemorrhagic ovarian cysts. Journal of ultrasound in medicine. 2002 Aug;21(8):879-86. htt ps://doi.org/10.7863/jum.2002.21.8.879 5. ?tefan RA, ?tefan PA, Mihu CM, Csutak C, Melincovici CS, Crivii CB, Malu?an AM, Hî?u L, Lebovici A. Ultrasonography in the differentiation of endometriomas from haemorrhagic ovarian cysts: the role of texture analysis. Journal of Personal ized Medicine. 2021 Jun 28;11(7):611. https://doi.org/10.3390/ jpm11070611 6. Gavankar A, Gawai J. Haemorrhagic Ovarian Cyst:“A Case Re port”. International Journal of Research and Reports in Gynae cology. 2022 Apr 15;5(1):120-24. 7. Qayoom R. Research on History of PCOS (Polycystic Ovarian Syndrome) Marz Akyas Khusyatur Rahim. International Jour nal of Scientific Development and Research. 2023 May; 8 (5): 1135-39. 8. Farook F, Rumaiza J. A review on effective single drugs (mufrad dawa) used in the unani system for the management of poly cystic ovarian syndrome (marz e aghziya e khussiyatur reham) syndrome: a review. 22:1-5 9. Syed AF, Ahmed J. Marz Akyas Khusyatur Rehm (Polycys tic Ovary Syndrome): An Overview. Pathophysiology. 2016; 9:11:119-128. 10. Ministry of AYUSH. National Formulary of Unani Medicine. Part V. New Delhi: Central Council for Research in Unani Medi cine; 2008. Jul: 90-91. 11. Ministry of AYUSH. National Formulary of Unani Medicine. Part I. New Delhi: Central Council for Research in Unani Medi cine; 2006 :93